In its first financial results announcement after the spin-off, Samsung Bioepis recorded FY2025 revenue of KRW 1.672 trillion, highest annual revenue in its 14-year history Excluding milestone ...

Samsung Bioepis, a subsidiary of Samsung Epis Holdings, achieved its highest annual sales performance last year. According to ...

The global pharmaceutical industry will generate more than $1.2 trillion in sales in 2026, according to Statista. The oncology segment alone is expected to generate $232 billion in sales this year.

We support Toronto seniors and people in long-term care to have the healthiest, most fulfilling lives possible through exceptional care and services. Find highlights below from the past year that show ...

Amgen delivered a strong fourth quarter of 2025 and looks well-positioned to absorb the LOEs on Prolia, Xgeva, and Ravicti in ...

CVS Caremark will begin offering osteoporosis biosimilars Ospomyv and Stoboclo, as well as generic teriparatide, Bonsity and ...

Amgen has denied a request by the FDA to voluntarily withdraw its rare disease drug Tavneos from the market, the company said ...

CVS Health®   today announced new steps to further help customers expand adoption of lower-cost biosimilar medications. Effective April 1, 2026, CVS Caremark will begin offering osteoporosis ...

Amgen Inc (AMGN) reports robust sales growth with 14 blockbuster products, while navigating competitive pressures and strategic pivots.

Angitia Biopharmaceuticals has unveiled its second mega-round in 14 months, revealing a $130 million series D financing that positions the biotech to take three bone disease prospects deeper into the ...

On Dec 19, 2025, the US Food and Drug Administration (FDA) announced a major milestone by qualifying total hip bone mineral density (BMD), assessed by dual-energy X-ray absorptiometry, as a surrogate ...